| Horseshoe Crab Home | Education Home | Fisheries Home | DNR Home |
|
|
Discovery of LALThe clotting properties of the horseshoe crab’s blood were first documented by W.H. Howell of Johns Hopkins University in 1885. This discovery is important to later research performed at the Wood’s Hole Marine Biological Laboratory (MBL) located at Wood’s Hole, Massachusetts. During the 1950’s, the MBL scientist Fredrick Bang discovered the component of the blood that caused clotting to occur. |
|
The white blood cells (amebocytes) within the horseshoe crabs blood clotted when exposed to endotoxins. Later, Dr. Bang and Dr. Jack
Levin developed a method for detecting endotoxins using an extract of the white blood cells called Limulus Amebocyte Lysate (LAL).
What are Endotoxins? During the late 1800’s, vaccinations were being developed to combat certain diseases. In many cases, people that where given these vaccines became sick with an illness called ‘injection fever’. Years later, injection fever was discovered to be an immune response to the presence of endotoxins in two types of bacteria. Gram-negative bacteria is the one type commonly found in aquatic environments. It is called gram-negative because the bacteria do not become stained during the Gram staining process.
How the LAL Test Works ![]() The LAL test has several advantages over the previously used Rabbit pyrogen test. LAL delivers faster results than the 3 hours it takes the rabbit test to show results and it can detect lower levels of endotoxin. The following medical products are typically tested for endotoxins using the LAL test: IV-solutions, dialysis tubing, pacemakers, other surgical implants, vaccines and other injectable medicines. Another test using LAL called the chromogenic substrate method creates a color rather than a clot to detect endotoxins. The LAL reagent turns a yellow color. The degree of coloration measured after a fixed period of time indicates the presence and quantity of endotoxins in the sample.
Producing the LAL Test The blood is placed in a centrifuge to separate the amebocytes from the blue haemolymph that comprises the supernatant. Distilled water is then added to the separated amebocytes. The added water will eventually cause the cells to burst, or lyse. Clotting proteins inside the cells are released and separated from the rest of the solution. The collected proteins are further processed into the powdered LAL product.
Currently, three biomedical companies produce the LAL in the United States. They are Associates of Cape Cod (Falmouth, Massachusetts), BioWhittaker (Walkersville, Maryland) and Charles River Endosafe (Charleston, South Carolina). The FDA regulates each company’s horseshoe crab bleeding process, however, a separate state collection permit requires the crabs to be returned to the same location they were taken from or, as of 2001, sold to the bait industry. Photographs by BioWhittaker, Inc.
|
| Updated July 29, 2005 |